Krish S Krishnan

KRYS CEO Krishnan sold 25,000 shares for $7.7M (avg $308.12) via scheduled 10b5-1 plan on 2026-06-04

Krish S Krishnan, President and CEO of Krystal Biotech, executed 11 separate sales totaling 25,000 shares for $7,702,983.82 on 2026-06-04, reducing his holdings from 1,475,253 shares to 1,450,253 shares (a -1.7% net change). This transaction is part of a pre-arranged 10b5-1 trading plan adopted on 2025-09-04, meaning it was scheduled rather than discretionary. The blended average sale price was $308.12, slightly above the current price of $301.00. The company's fundamentals show strong growth (annual revenue growth of +33.9%) and profitability (net income of $55,932,000.00 on revenue of $116,357,000.00 in the latest quarter), though the P/E ratio of 39.45 reflects investor expectations. Given the scheduled nature of the transaction under a 10b5-1 plan, this sale does not convey timing-dependent signals; it represents predetermined portfolio activity that proceeded regardless of current market conditions.

CEO Krishnan sold 25,000 shares for $6.6M via 10 separate transactions on 2026-03-04 under pre-arranged 10b5-1 plan

Krishnan Krish S, President and CEO, executed 10 separate sales totaling 25,000 shares for $6,579,164.35 across a blended average price of $263.17 on 2026-03-04. This represents a -1.7% reduction in his holdings to 1,475,253 shares. The transaction was conducted under a 10b5-1 trading plan adopted on 2025-09-04, making it a scheduled, non-discretionary sale. The multiple tranches at incrementally rising prices ($257.31 to $266.56) reflect algorithmic execution rather than a single block trade. Since the sale is pre-arranged and scheduled, no inference about CEO confidence or market timing can be drawn from this filing alone.

KRYS CEO Krishnan sold 50,000 shares for $11.0M on 2025-12-04 via pre-arranged 10b5-1 plan adopted 2025-09-04

Krishnan Krish S, President and CEO of Krystal Biotech, executed 16 separate sales totaling 50,000 shares for $11,007,446.72 on 2025-12-04, reducing his holdings from 1,463,711 shares to 1,413,711 shares (a 3.4% reduction). The sales occurred across a range of prices from $214.25 to $222.38, with a blended average price of $220.15. This transaction is part of a pre-arranged 10b5-1 trading plan adopted on 2025-09-04, meaning it is scheduled rather than discretionary. The CEO retains substantial holdings of approximately 1.41M shares post-transaction, indicating continued material equity stake in the company.

CEO Krishnan sells 35,873 shares across 9 transactions for $5.4M; part of pre-arranged 10b5-1 plan.

Krishnan Krish S, President and CEO of Krystal Biotech, executed 9 separate sales totaling 35,873 shares for $5,395,000.82 between July 14–16, 2025, at prices ranging from $150.00 to $151.79, with a blended average of $150.39. This activity reduced his holdings from 1,474,584 shares to 1,438,711 shares, a decline of 2.4% of pre-transaction holdings. The transaction is governed by a pre-arranged 10b5-1 trading plan, meaning the sales were scheduled in advance rather than discretionary decisions. The multi-day execution across a narrow price band and the structured nature of the plan remove this activity from the category of opportunistic or market-driven decisions by the CEO.

CEO Krishnan Krish S sold 14,127 shares for $2,122,834.96 via scheduled 10b5-1 plan adopted Sept 2024.

Krishnan Krish S, President and CEO of Krystal Biotech, executed 6 separate sales totaling 14,127 shares for $2,122,834.96 at a blended average price of $150.27 across July 9-10, 2025. This activity is part of a pre-arranged 10b5-1 trading plan adopted on 2024-09-12, meaning the sales were scheduled in advance and not discretionary. The CEO retains 1,456,711 shares post-transaction, representing a net reduction of approximately 1.0% versus pre-transaction holdings of 1,470,838 shares. Because these sales are governed by a 10b5-1 plan rather than market-driven timing decisions, the transaction reflects a pre-established divestiture schedule rather than a near-term signal about company prospects.

CEO Krishnan sells 50,000 shares (3.3% of holdings) for $8.9M at blended avg $177.79; stock +18.3% (30d), down 17.0% from 52-week high.

Krishnan Krish S, President and CEO of Krystal Biotech, executed 10 separate sales totaling 50,000 shares for $8,889,524.57 on 2025-03-13 at prices ranging from $175.83 to $179.57, with a blended average price of $177.79. This reduces his post-transaction holdings to 1,463,711 shares, a net decrease of 3.3% from his pre-transaction position. The stock is currently at $177.37, up 18.3% over 30 days but remains 17.0% below its 52-week high of $213.66. His prior sales at Krystal Biotech (5 trades in December 2024) averaged negative 30-day returns (-8.3% mean) but positive 90-day returns (+6.4% mean), with none of those trades being well-timed at the 90-day horizon (all returned positive, meaning the stock rose after he sold). Cross-ticker, his broader track record shows 20 prior sells with a 15.00% well-timed rate at 90 days, substantially below median performance for consistently profitable sell-timing. The stock trades at a P/E of 39.15 on quarterly revenue of $83.8M (up 473.0% year-over-year) and net income of $27.2M, reflecting a high-growth biotech profile where recent momentum may be pulling the stock into overbought territory relative to historical range.

CEO Krishnan sold 50,000 shares (50.0K) at blended avg $164.80 on 2024-12-13 via 10b5-1 plan

Krishnan Krish S, President and CEO of Krystal Biotech, executed 17 separate sales totaling 50,000 shares for $8,240,023.06 across a range of prices from $163.07 to $171.63 on 2024-12-13, with a blended average price of $164.80. This transaction is governed by a 10b5-1 trading plan adopted on 2024-06-13, meaning the sales were scheduled and pre-arranged rather than discretionary decisions made on the transaction date. Post-sale, Krishnan retained 1,475,882 shares (1.48M shares), representing a reduction of 3.3% from pre-transaction holdings of 1,525,882 shares (1.53M shares). The scheduled nature of the plan removes the possibility of any timing inference; the sale reflects only pre-established parameters and calendar execution.

KRYS CEO Krishnan sells 50,000 shares ($9.9M) on 2024-09-12 at blended avg $197.77

Krishnan Krish S, President and CEO of Krystal Biotech, executed 15 separate sales totaling 50,000 shares for $9,888,276.35 on 2024-09-12, reducing holdings by 3.2% to 1,500,882 shares post-transaction. The stock traded in a range of $195.16 to $201.81 across the transactions, with a blended average price of $197.77, versus a current price of $201.58. His prior 5 open-market sales at KRYS (all on 2024-06-11) showed 30-day returns of +11.4% to +15.8%, but notably none were well-timed at the 90-day mark—the stock rose following each prior sale, suggesting the executive sold before continued momentum. The magnitude ($9.9M across a $5.8B market cap) and the multi-tranche execution pattern warrant monitoring to determine whether this represents a one-time liquidity need or a broader shift in conviction at a company posting net income of $15,568,000.00 on revenue of $70,284,000.00.